Search

Highlights • Myxoid liposarcoma is a rare mesenchymal tumor of the bladder with only a few cases reported in the literature. • It is difficult to diagnose and carries a poor prognosis. • The primary treatment is complete surgical resection which is usually followed by adjuvant chemotherapy. • We report a case of 26 year female with mesenchymal tumor of the bladder presenting as a large abdominal mass., Introduction Myxoid liposarcoma of the bladder is a rare mesenchymal tumor which is difficult to diagnose and carries a poor prognosis. The primary treatment is complete surgical resection which is usually followed by adjuvant chemotherapy. Presentation of case We report a case of 26 years female who presented with a large abdominal mass and was initially misdiagnosed to be arising from ovaries and subsequently discovered to be a mesenchymal tumor arising from the bladder. Discussion Myxoid liposarcoma is an exceedingly rare but aggressive mesenchymal tumor of the bladder often with misleading imaging appearances. Conclusion Surgical resection, when feasible, plays the leading role in its management, and should be attempted in all potential patients.

Objective: The incidence of genitourinary sarcomas is very low, so the published reports in the literature are very limited. We aimed to present our experiences of eight cases originating from various genitourinary organs treated in our clinic. Materials and Methods: We retrospectively reviewed the data and postoperative follow-up findings of eight cases aged 3-72 years who were diagnosed as genitourinary sarcoma and treated between January 2013 and February 2017. Results: All eight cases were male and the mean age at diagnosis was 47.87 (range = 3-72) years. The most common site was paratesticular area (five cases, 62.5%) followed by kidney (two cases, 25%) and prostate (one case, 12.5%). Histological types of tumors were rhabdomyosarcoma (RMS) (two cases, 25%), liposarcoma (LPS) (two cases, 25%), leiomyosarcoma (LMS) (two cases, 25%), synovial sarcoma (one case, 12.5%) and malignant fibrous histiostoma (MFH) (one case, 12.5%). At a median follow-up of 23.5 (range = 4-62) months, the recurrence-free and progression-free survival rate was 50%, while the overall survival rate was 50%. Among the five paratesticular sarcomas, the worst prognosis was seen in LMS (local recurrence at the 4th, overall survival was 28 months) and MFH (local recurrence at the 8th, overall survival was 33 months). Among all sarcoma cases, LMS and synovial sarcoma were the histologic types with the worst prognosis. The histological types with the best prognosis were LPS and RMS with no recurrence or progression during follow-up. In all cases with a median tumor size of 52.5 mm (range = 11-210), LPS was found to have a better prognosis, although the largest tumor size was in renal LPS. According to FNCLCC classifications, local recurrence-free survival was significantly higher in grade II sarcomas than in grade III (p=0.042). Conclusion: Histopathological features and oncologic outcomes of genitourinary sarcomas differ. The prognosis of paratesticular sarcomas is better than other genitourinary organ sarcomas. LPS has higher cure rates after treatment in histological subtypes. The prognosis of histopathologically poorly differentiated subtypes and high-grade tumors is poor. If adjuvant treatments are not added, they may be fatal with local recurrence or distant metastasis in a short time.